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ception. A randomized, double-blind, placebo-controlled
Thus supplementary administration of anti-progesterone to a two-centre study was conducted in 50 healthy volunteers.
progestagen-only-contraceptive regimen might improve cycle Serum luteinizing hormone (LH), follicle stimulating horcontrol possibly as a result of blocking progestagen receptors mone (FSH), oestradiol and progesterone concentrations, on the endometrium (Hodgen et al., 1994; Heikinheimo et al. , and follicle number and size were studied, as well as 1996). The combination of a POP and an anti-progestagen endometrial thickness, which was assessed by transvaginal may yield a new type of oestrogen-free oral contraceptive, sonography at least twice weekly during a single medication with improved bleeding characteristics compared to the clascycle (cycle 3-5). Forty-eight women were evaluated (Org sical POP.
31710, n ⍧ 25; placebo, n ⍧ 23). Seven ovulations were
Org 31710 is a strong anti-progestagen with low antiobserved in the treated group versus none in the placebo glucocorticoid activity and weak androgenic/anti-androgenic group. LH concentrations were higher on days 9 and 11 and anabolic properties (Mizutani et al., 1992; Kloosterboer et al., 1994) . The present study was designed to assess the and oestradiol concentrations lower on day 3 in the treated effects of Org 31710 or a placebo on pituitary-ovarian activity group, irrespective of whether ovulation occurred. No and the effects on endometrial thickness during a continuous parameter could predict ovulation. Endometrial thickness oral 75 µg desogestrel (DSG) progestagen-only regime. was greater on cycle days 7-13 and 19 in the treated group. However, within the Org 31710 group, no significant differences were found in volunteers who did or did not Material and methods ovulate. Observed differences may be attributed to a competitive effect of Org 31710 with progestagen-induced Introduction of the study medication in improving cycle control.
The ethics committee of both centres approved the study. The
Insufficient cycle control represents the major problem associstudy was completed according to the guidelines of good clinical ated with any progestagen-only-contraceptive regimen (Belsey, practice and conducted in full compliance with the World Medical 1988; Broome and Fotherby, 1990; Shoupe et al., 1991) . ing is often present. This may be caused by a direct effect of and 29 kg/m 2 and the use of barrier methods of contraception during A single investigator in each centre using a 7.5 MHz transvaginal probe performed all sonographic measurements. Follicular activity FSH ϭ follicle stimulating hormone; LH ϭ luteinizing hormone.
was assessed by means of vaginal ultrasound, counting the number of follicles after scanning each ovary from the inner to the outer margin in a longitudinal cross-section, as previously described (Pache Table II . Distribution of maximum follicle diameters and maximum van Santbrink et al., 1995) . The diameter was taken to progesterone concentrations during a single, frequently monitored cycle be the mean of the size of the follicle in a longitudinal and an antero-(medication cycles 3-5) comparing ovarian activity during Org 31710 and placebo use in women taking 75 µg desogestrel progestagen-only posterior plane. Beyond a diameter of 10 mm, measurements in three contraceptive pills planes were performed. Follicles ജ 10 mm were considered dominant (Pache et al., 1990; van Santbrink et al., 1995) . On every occasion, trations were determined by radioimmunoassay as previously 21-30  16  67  8  35 described (De Jong et al., 1974 of variation (CV) were Ͻ4.0 and Ͻ6.4% for FSH, Ͻ15.5, and Ͻ14.1% for LH, Ͻ15 and Ͻ18% for oestradiol , and Ͻ16 and Ͻ17%
a One subject could not be classified in maximum follicle diameter due to for progesterone respectively. Samples from one individual were run missing data.
in the same assay.
b Distribution not statistically significant. c Distribution statistically significant (P ϭ 0.005).
Data analysis
Results are presented as mean and 95% confidence interval unless
Pituitary-ovarian activity stated otherwise. Study parameters were compared using the MannWhitney U test. Differences were considered to reach statistical Forty-eight women were included in the evaluation of pituitary significance when P Ͻ 0.05.
activity. Summary statistics for FSH, LH, oestradiol, progesterone, and follicle diameter are presented in Table I . Mean and maximum progesterone concentrations were significantly Results higher in the Org 31710 group (P ϭ 0.001 and 0.01 respectDemographics ively; independent t-test). The distribution of all studied parameters was tested with the Mann-Whitney U test and did Two women were excluded from analysis due to protocol violations (both placebo). All remaining 48 volunteers (25 Org not show any statistically significant differences. Follicle diameters and progesterone serum values were categorized to 31710, 23 placebo) completed the study. Relevant demographic parameters were not statistically different between the two allow for a classification based on contraceptive efficacy and are displayed in Table II . There were no statistically significant medication groups [age 29.2 Ϯ 6.0 versus 29.1 Ϯ 5.4 years, weight 65.5 Ϯ 9.5 versus 65.6 Ϯ 10.2 kg, height 167.3 Ϯ 7.8 differences in the distribution of follicle categories between the two medication groups. However, the categories for progesversus 168.0 Ϯ 5.3 cm; Org 31710 (n ϭ 25) versus placebo (n ϭ 23), mean Ϯ SD].
terone designed to discriminate for ovulation (Shepard and Senturia, 1977) indicated that ovulation was significantly more Org 31710 group). The correlation was stronger when there was an ovulation during the study cycle [Pearson's correlation frequent in the Org 31710 group (P ϭ 0.005; χ 2 test). In six out of seven volunteers in which a serum progesterone Ͼ10 coefficient: r ϭ 0.302 versus r ϭ 0.42; P ϭ 0.01 comparing ovulatory versus non-ovulatory Org 31710 users (data not nmol/l was found, sonographic signs for ovulation were present. In the remaining subject one ovary could not be visualized at the shown)].
In the Org 31710 group, no statistically significant differpresumed moment of ovulation. Pituitary-ovarian parameters appeared normal in those women for whom ovulation was ences were found in endometrial thickness in volunteers who did or did not ovulate (Figure 4b ). Comparing all non-ovulatory observed: LH peak 15.4 Ϯ 10.1 IU/l; FSH peak 6.7 Ϯ 1.1 IU/ l; pre-ovulatory follicle diameter 21.0 Ϯ 4.8 mm; oestradiol volunteers, endometrial thickness again showed statistically significant differences on cycle days 7 to 13 and cycle day 19 peak 664 Ϯ 237 pmol/l; maximum progesterone concentrations were 26.0 Ϯ 11.0 nmol/l (mean Ϯ SD). Ovulation was mostly (P Ͻ 0.01; Figure 4c ). observed around mid-cycle, i.e. in between monthly Org 31710 or placebo administration: day 8, 9, 10, 11, 12 (two subjects, Discussion one without ultrasound conformation) and day 13. In seven women (three placebo, four Org 31710) sonographic suggestion
In this study, potential effects of a timed intermittent single dose of Org 31710 on pituitary-ovarian activity and endometrial for ovulation (sudden disappearance of a follicle Ͼ20 mm) was observed without a progesterone rise in the next 7 days thickness in healthy volunteers using 75 µg desogestrel progestagen-only contraception were evaluated. nor with a concomitant LH peak or pre-ovulatory oestradiol concentrations.
The contraceptive mode of action of progestagen-onlycontraceptives is suppression of ovulation, suppression of In Figure 1 parameters of pituitary-ovarian activity are displayed during the monitored medication cycle of both midcycle peaks of LH and FSH and peripheral effects on cervical mucus, Fallopian tube and endometrium (McCann and groups. There were no statistically significant differences between the observations of the two centres. Since evaluation Potter, 1994) . The effect of progestagen-only-contraceptives on the hypothalamic-pituitary-ovarian axis is incompletely did not take place on a daily basis, each parameter is pooled for two consecutive cycle days (i.e. the first data set from documented. Progestagens exercise both negative and positive feedback actions on the hypothalamic pulse generator cycle days 1 and 2, 3 and 4, etc.). LH concentrations were significantly higher in the Org 31710 group on day 9/10 (P depending on dosage and chemical structure (Hemrika, 1993) . Intra-ovarian regulation of folliculogenesis is also postulated Ͻ 0.001) and 11/12 (P ϭ 0.002). Furthermore, oestradiol concentrations were significant lower in the Org 31710 group to be affected through progesterone receptors in the theca layer (Hild-Petito et al., 1988) . Serum FSH concentrations seem to on days 3 and 4 (P ϭ 0.04). Although mean progesterone values were higher 'mid-cycle' in the Org 31710 group due be less affected (Tafurt et al., 1980) , but generally peak concentrations of LH and FSH are diminished (Landgren et al. , to the seven observed ovulations, this did not reach statistical significance (Mann-Whitney U test). Since ovulation only 1979; Kim Bjorklund et al., 1992) . Ovarian activity ranges from complete suppression, dominant follicle formation without occurred in the Org 31710 group, the ovulatory (n ϭ 7) and non-ovulatory (n ϭ 18) Org 31710 users were compared (data ovulation or luteal activity, ovulation with luteal insufficiency to normal ovulatory patterns (Landgren and Diczfalusy, 1980 ; not shown). Figure 2 shows that significant differences were found on day 9 for follicle diameter (P ϭ 0.05) and oestradiol Tayob et al., 1986; Shaaban et al., 1993) . In progestagen-onlycontraceptive users, ovulatory cycles have been reported in up concentration (P ϭ 0.01), on day 21 for LH concentration (P ϭ 0.001) and on days 13 to 21 for progesterone (P Ͻ to 84% of women (McCann and Potter, 1994) . In this study, none of the 23 studied cycles in women using 0.01). In order to discriminate whether the differences between the Org 31710 group versus the placebo group were due to 75 µg DSG POP demonstrated an ovulatory pattern, while this occurred in 7/25 (28%) of cycles in the Org 31710 group. the occurrence of ovulations, the non-ovulatory volunteers using Org 31710 (n ϭ 18) were compared with the (nonThis finding is in agreement with an earlier study regarding pituitary-ovarian activity during the use of 75 µg DSG POP ovulatory) placebo-group (n ϭ 23) (Figure 3 ). Oestradiol concentrations remained significantly different on day 3 and (Rice et al., 1996) . However, comparable concentrations of FSH, LH, follicle diameter, and oestradiol were observed in LH concentrations on days 9 and 11 as was observed in the complete Org 31710 versus placebo groups. This indicates the Org 31710 and placebo groups. The data in this study corroborate the observations that although gonadotrophin peak that the observed differences in oestradiol and LH between Org 31710 and placebo were not only related to the occurrence concentrations are suppressed, dominant follicles commonly emerge and moderate oestradiol concentrations are present of ovulation.
during POP therapy.
Endometrial thickness
There were no statistically significant differences in overall (mean concentrations throughout a single cycle) or maximum The endometrium was significantly thicker in the Org 31710 group on cycle days 7 to 13 and cycle day 19 compared to concentrations of LH, FSH, oestradiol, and follicle diameter comparing Org 31710 users who did or did not ovulate. the placebo group (Figure 4a ). There was a weak but significant correlation between oestradiol concentrations and endometrial Furthermore, differences in sequential oestradiol concentrations and follicle diameter only reached statistical significance thickness (Pearson's correlation coefficient: r ϭ 0.305, P ϭ 0.01 for the placebo group and r ϭ 0.317, P ϭ 0.01 for the on day 9 and for LH on day 21. Although there was a tendency , n ϭ 23). Each parameter was pooled for 2 consecutive cycle days (i.e. the first data set from cycle days 1 and 2, 3 and 4, etc.). LH ϭ luteinizing hormone; FSH ϭ follicle stimulating hormone.
for ovulation to occur at midcycle (i.e. in between Org 31710
Relatively small numbers in this study may prevent the detection of a causative correlation and mere coincidence doses), no parameter could be identified which could predict ovulation in the Org 31710 group. could be responsible for the ovulations to occur only in the Org 31710 group. However, a possible explanation for the Other attempts to combine an anti-progestagen and a progestagen for contraception have been reported. A combination of (timed) ovulations in the Org 31710 group could be postulated to occur as the result of two mechanisms. Firstly, Org 31710 mifepristone was given at a dose of 50 mg/day on cycle days 9-11 and 27-29 combined with medroxyprogesterone acetate could reduce the progestagen-induced inhibition of pituitaryovarian activity merely by competition of the anti-progestagen on cycle days 17-26 (Kekkonen et al., 1995) . Twenty of 32 cycles (63%) did not show evidence of ovulation (progesterone with the progestagen DSG. Alternatively, the anti-oestrogenic activity of Org 31710 could interfere with oestradiol-mediated ജ9 nmol/l) and serum oestradiol concentrations were statistically significantly higher after mifepristone administration.
feedback mechanisms, resulting in increased follicular sensitiv- , n ϭ 18). Each parameter was pooled for 2 consecutive cycle days (i.e. the first data set from cycle days 1 and 2, 3 and 4, etc.).
ity to FSH and/or increased pituitary sensitivity to release LH. mifepristone in the guinea pig inhibited ovulation in a dosedependent fashion (Batista et al., 1991) . In normally cycling Previous studies have indicated that mifepristone can disrupt ovulation by inhibiting the positive feedback effect of oestrowomen, a dosage of 1 mg/ day delayed ovulation without affecting gonadal steroid production (Batista et al., 1992) . gens and, hence, prevent or delay the occurrence of a preovulatory LH surge (Baird et al., 1995) . This effect may not
Baird and co-workers demonstrated that mifepristone 1 mg/ day continuously was able to disrupt ovulation by inhibiting occur at the concentration of the pituitary but rather at the hypothalamus (Heikinheimo et al., 1996) . Cyclic administrathe positive feedback effect of oestrogens to produce the LH surge while basal concentrations of gonadotrophins remained tion of mifepristone alone in different regimens showed partial inhibition of oestradiol secretion and suppressed progesterone unchanged (Baird et al., 1995) . Ovulation was delayed by approximately 7 days. These findings support the hypothesis concentrations (Spitz et al., 1993) . Daily administration of , n ϭ 18) versus desogestrel ϩ placebo group ( , n ϭ 23). Each parameter was pooled for 2 consecutive cycle days (i.e. the first data set from cycle day 1and 2, 3 and 4, etc.). that a direct effect of an anti-progestagen on hypothalamic- Landgren et al., 1994; Darney et al., 1996) , whereas others indicate that there might well be a relationship between pituitary regulation could be responsible for the observation that ovulation clustered around midcycle in the current study.
bleeding pattern and endogenous hormonal activity (Zalanyi et al., 1984; Shoupe et al., 1991) . The rationale of adding Org Probably the most important disadvantage of current progestagen-only contraceptives is the unpredictable bleeding pattern.
31710 to a progestagen-only contraceptive regimen is derived from the concept that the addition of an anti-progestagen might This bleeding pattern is often thought to develop as a result of both endogenous and exogenous endocrine influences on improve cycle control. The anti-progestagen mifepristone was found to block oestrogen-induced endometrial proliferation in the endometrium. However, reports are conflicting. Some studies have failed to demonstrate a relationship between primates due to a non-competitive anti-oestrogenic activity (Van Uem et al., 1989) . This action was found to be dosebleeding patterns and ovulation, ovarian hormones or exogenous progestagen concentrations (Kim Bjorklund et al., 1991;  dependent in the presence of physiological concentrations of oestradiol. Mifepristone was antagonistic in the presence of progesterone, but demonstrated endometrial progestational effects at low doses and an antiproliferative (anti-oestrogenic) effect at higher doses in the absence of progesterone (Wolf et al., 1989) . Bleeding patterns during the use of the studied medication are currently being analysed for all 104 subjects in which a more cyclic bleeding pattern is observed in the subjects of the Org 31710 treatment group. In the Org 31710 there was no correlation between the occurrence of ovulation and the bleeding pattern (results will be reported separately). Continuous administration of mifepristone 1 mg/day showed endometrial morphology similar to that seen in infertile women with luteal phase defects (Batista et al., 1992) . Onapristone, another anti-progestagen, also demonstrated an inhibitory effect on endometrium growth in primates (Ishwad et al., 1993; Neulen et al., 1996) . Both an increase in the endometrial oestradiol and progesterone receptor concentrations (Neulen et al., 1996) and the oestradiol receptor of the endometrial stroma alone have been reported (Murphy et al., 1995) . In this study, a statistically significant increase of endometrial thickness was found following the use of Org 31710, irrespective of the occurrence of ovulation. This difference gained statistical significance on days 7, 9, 11, 13 and 19. Although continuous administration of mifepristone blocks oestrogeninduced endometrial proliferation, a single dose of Org 31710 in this study was associated with an increase in endometrial thickness. The significant increase of endometrial thickness compared with the placebo group was not associated with higher oestradiol concentrations. A direct effect on the endometrium is therefore postulated, possibly through an increase in endometrial oestrogen receptors. Histological classification of the endometrium is mandatory to explore this further.
In conclusion, in this study the influence of a single monthly dose of the anti-progestagen Org 31710 was assessed during a 75 µg DSG continuous regimen of POP. The data suggest that Org 31710 may temporarily decrease oestradiol production, presumably through a direct effect on ovarian function. Furthermore, it may disrupt oestradiol-related feedback mechanisms through an effect at the hypothalamic-pituitary level and delay the LH surge. This may increase the likelihood of ovulation occurring during the POP cycles studied. Finally, there appears to be a direct effect on endometrial proliferation. Comparisons of the effects of Org 31710 with known mifepristone effects should be made with caution since differences may be caused by different mechanisms of action and/or different dosing schedules. Combining anti-progestagens with progestagen-only contraceptives could result in improved bleeding characteristics due to temporarily diminishing the effect of the progestagen and / or through the direct (proliferative) effect on endometrium. However, effects on the hypothalamic-pituitary-ovarian axis and peripheral contraceptive modalities of progestagenonly contraceptives following the use of anti-progestagens 
